Literature DB >> 16981197

Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype.

Andrea Salmaggi1, Amerigo Boiardi, Maurizio Gelati, Annamaria Russo, Chiara Calatozzolo, Emilio Ciusani, Francesca Luisa Sciacca, Arianna Ottolina, Eugenio Agostino Parati, Caterina La Porta, Giulio Alessandri, Carlo Marras, Danilo Croci, Marco De Rossi.   

Abstract

We investigated in vitro the properties of selected populations of cancer stem-like cells defined as tumorospheres that were obtained from human glioblastoma. We also assessed their potential and capability of differentiating into mature cells of the central nervous system. In vivo, their tumorigenicity was confirmed after transplantation into the brain of non-obese diabetic/severe combined immunodeficient (NOD-SCID) mice. The angiogenic potential of tumorospheres and glioblastoma-derived cells grown as adherent cells was revealed by evaluating the release of angiogenic factors such as vascular endothelial growth factor and CXCL12 by ELISA, as well as by rat aortic ring assay. The proliferative response of tumorospheres in the presence of CXCL12 was observed for the first time. Multidrug resistance-associated proteins 1 and 3 as well as other molecules conferring multidrug resistance were higher when compared with primary adherent cells derived from the same tumor. Finally, we obtained cells from the tumor developing after grafting that clearly expressed the putative neural stem cell marker CD133 as shown by FACS analysis and also nestin and CXCR4. The cells' positivity for glial fibrillary acidic protein was very low. Moreover these cells preserved their angiogenic potential. We conclude that human glioblastoma could contain tumor cell subsets with angiogenic and chemoresistance properties and that this chemoresistance potential is highly preserved by immature cells whereas the angiogenic potential is, to a higher extent, a property of mature cells. A better understanding of the features of these cell subsets may favor the development of more specifically targeted therapies. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981197     DOI: 10.1002/glia.20414

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  100 in total

1.  Clinical significance of Polycomb gene expression in brain tumors.

Authors:  Francesco Crea; Elaine M Hurt; William L Farrar
Journal:  Mol Cancer       Date:  2010-09-30       Impact factor: 27.401

2.  The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.

Authors:  Muhammad Jamal; Barbara H Rath; Patricia S Tsang; Kevin Camphausen; Philip J Tofilon
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

Review 3.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

4.  Microenvironmental regulation of glioblastoma radioresponse.

Authors:  Muhammad Jamal; Barbara H Rath; Eli S Williams; Kevin Camphausen; Philip J Tofilon
Journal:  Clin Cancer Res       Date:  2010-10-29       Impact factor: 12.531

5.  Spheroid-based drug screen: considerations and practical approach.

Authors:  Juergen Friedrich; Claudia Seidel; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  Nat Protoc       Date:  2009-02-12       Impact factor: 13.491

6.  The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence.

Authors:  Ichiyo Shibahara; Yukihiko Sonoda; Ryuta Saito; Masayuki Kanamori; Yoji Yamashita; Toshihiro Kumabe; Mika Watanabe; Hiroyoshi Suzuki; Takashi Watanabe; Chikashi Ishioka; Teiji Tominaga
Journal:  Neuro Oncol       Date:  2013-05-07       Impact factor: 12.300

7.  Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Authors:  Franz J Zemp; Xueqing Lun; Brienne A McKenzie; Hongyuan Zhou; Lori Maxwell; Beichen Sun; John J P Kelly; Owen Stechishin; Artee Luchman; Samuel Weiss; J Gregory Cairncross; Mark G Hamilton; Brian A Rabinovich; Masmudur M Rahman; Mohamed R Mohamed; Sherin Smallwood; Donna L Senger; John Bell; Grant McFadden; Peter A Forsyth
Journal:  Neuro Oncol       Date:  2013-04-12       Impact factor: 12.300

Review 8.  The role of the CXCR4 cell surface chemokine receptor in glioma biology.

Authors:  Moneeb Ehtesham; Elliot Min; Neil M Issar; Rebecca A Kasl; Imad S Khan; Reid C Thompson
Journal:  J Neurooncol       Date:  2013-03-14       Impact factor: 4.130

Review 9.  Brain cancer stem cells.

Authors:  Sara G M Piccirillo; Elena Binda; Roberta Fiocco; Angelo L Vescovi; Khalid Shah
Journal:  J Mol Med (Berl)       Date:  2009-09-29       Impact factor: 4.599

10.  Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery.

Authors:  D D Fang; Y J Kim; C N Lee; S Aggarwal; K McKinnon; D Mesmer; J Norton; C E Birse; T He; S M Ruben; P A Moore
Journal:  Br J Cancer       Date:  2010-03-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.